ReviewAnnals of intensive care2025
Critical insights for intensivists on Guillain-Barré syndrome.
Review in Annals of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Multiple organ failure following severe heat stroke complicated by AMSAN-type Guillain-Barré syndrome: a case report and literature review.BMC neurology · 2026Review
- Guillain-Barré syndrome following Plasmodium falciparum malaria in a child: a case report.Malaria journal · 2026Article
- Acute Management of Guillain-Barré Syndrome: A Narrative Review.Archives of internal medicine research · 2026Article
- Recurrent Neuro-Renal Syndrome With Acute Kidney Injury From Anti-Pan-Neurofascin Antibody Resurgence: A Case Report.Kidney medicine · 2026Article
- Infections and Syndromes Caused by Campylobacter.Microorganisms · 2026Review
- Article
- Effects of direct tracheostomy on ventilator weaning in patients intubated for Guillain-Barré syndrome.Annals of intensive care · 2026Article
- Beyond ventilator weaning: rethinking the role of tracheostomy in Guillain-Barré syndrome.Annals of intensive care · 2026Article
- Clinical outcomes and safety of efgartigimod in Guillain-Barré syndrome: a retrospective observation study.Frontiers in immunology · 2026Observational
- Weaning of neuromuscular patients: the reality is probably somewhere in between.Intensive care medicine · 2026Article
- A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy.Frontiers in immunology · 2026Article
- Characteristics of ventilator weaning in patients intubated for Guillain-Barré syndrome or myasthenia gravis: a nationwide multicenter study.Intensive care medicine · 2025Article
- Weaning from mechanical ventilation in myasthenic crisis according to WEAN safe: most patients experience intermediate or prolonged weaning with no differences between early and late-onset compared to very-late onset myasthenia Gravis.Annals of intensive care · 2025Article
- A unified spectrum model for the anti-GQ1b antibody syndromes: from pathophysiology to a new diagnostic framework.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guillain-Barré Syndrome (GBS) is a leading cause of acute flaccid tetraplegia worldwide, with an incidence of 1-2 cases per 100,000 people per year. Characterized by an immune-mediated polyneuropathy, GBS often follows infections or immunological triggers, including vaccinations. The syndrome is classified into three main subtypes based on electrophysiological findings: acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and acute motor sensory axonal neuropathy (AMSAN). The pathophysiology of GBS involves molecular mimicry between microbial antigens and nerve structures, particularly affecting gangliosides and myelin proteins. Diagnosis primarily relies on clinical history, with lumbar puncture and electroneuromyogram used to confirm and differentiate subtypes. Treatment includes intravenous immunoglobulins or therapeutic plasma exchange associated with symptomatic treatment, especially mechanical ventilation if needed. Prognosis is generally favorable with a low mortality rate (< 5%) overall, but neurological sequelae can occur. Current research continues to explore novel therapeutic approaches, including complement-targeted therapies. Despite advancements, progress in specific treatments has been limited, and ongoing evaluation of potential biomarkers such as neurofilament light chains may enhance prognosis prediction and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.